[go: up one dir, main page]

MX2018003202A - Formas cristalinas. - Google Patents

Formas cristalinas.

Info

Publication number
MX2018003202A
MX2018003202A MX2018003202A MX2018003202A MX2018003202A MX 2018003202 A MX2018003202 A MX 2018003202A MX 2018003202 A MX2018003202 A MX 2018003202A MX 2018003202 A MX2018003202 A MX 2018003202A MX 2018003202 A MX2018003202 A MX 2018003202A
Authority
MX
Mexico
Prior art keywords
crystalline forms
pharmaceutical compositions
crystalline
etrahydro
chloropyrimidin
Prior art date
Application number
MX2018003202A
Other languages
English (en)
Other versions
MX379014B (es
Inventor
Von Raumer Markus
Aissaoui Hamed
Boss Christoph
Siegrist Romain
Bouis Patrick
Hazemann Julien
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2018003202A publication Critical patent/MX2018003202A/es
Publication of MX379014B publication Critical patent/MX379014B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a una forma cristalina del ácido (S)-2-(8-((5-cloropirimidin-2-iI)(metil)amino)-2-fluoro-6,7,8,9-t etrahidro-5H-pirido[3,2-b]indol-5-iI)acético, a los procesos para la preparación del mismo, a las composiciones farmacéuticas que comprenden dichas formas cristalinas, a las composiciones farmacéuticas preparadas a partir de dichas formas cristalinas y a su uso como un medicamento, especialmente como moduladores del receptor CRTH2.
MX2018003202A 2015-09-15 2016-09-14 Formas cristalinas. MX379014B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015071060 2015-09-15
PCT/EP2016/071637 WO2017046125A1 (en) 2015-09-15 2016-09-14 Crystalline forms

Publications (2)

Publication Number Publication Date
MX2018003202A true MX2018003202A (es) 2018-06-08
MX379014B MX379014B (es) 2025-03-10

Family

ID=56979537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003202A MX379014B (es) 2015-09-15 2016-09-14 Formas cristalinas.

Country Status (18)

Country Link
US (1) US10351560B2 (es)
EP (1) EP3350179B1 (es)
JP (1) JP6833852B2 (es)
KR (1) KR20180053345A (es)
CN (1) CN108026093B (es)
AU (1) AU2016323262B2 (es)
CA (1) CA2993893A1 (es)
CL (1) CL2018000665A1 (es)
EA (1) EA035752B1 (es)
ES (1) ES2867757T3 (es)
HK (1) HK1255148A1 (es)
IL (1) IL258039A (es)
MX (1) MX379014B (es)
PH (1) PH12018500505A1 (es)
PL (1) PL3350179T3 (es)
TW (1) TWI711616B (es)
UA (1) UA123156C2 (es)
WO (1) WO2017046125A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117780C2 (uk) 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
EP4143315A1 (en) 2020-04-28 2023-03-08 The Broad Institute Inc. <smallcaps/>? ? ?ush2a? ? ? ? ?targeted base editing of thegene

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
AU2001250206A1 (en) 2000-04-12 2001-10-30 Merck Frosst Canada Ltd Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
JP4279561B2 (ja) 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
HUP0500014A3 (en) 2001-12-14 2010-06-28 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) and pharmaceutical compositions containing them
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003097598A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Composé comprenant un antagonisme du récepteur de pdg2
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
US7618979B2 (en) 2002-10-30 2009-11-17 Merck Frosst Canada Ltd. Pyridopyrrolizine and pyridoindolizine derivatives
WO2004078719A1 (ja) 2003-03-06 2004-09-16 Ono Pharmaceutical Co., Ltd. インドール誘導体化合物およびその化合物を有効成分とする薬剤
AU2004240705A1 (en) 2003-05-20 2004-12-02 Merck Frosst Canada & Co. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
CA2527773A1 (en) 2003-06-12 2004-12-23 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines as dp receptor antagonists
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005033099A2 (en) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
AU2004283139A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
ES2326896T3 (es) 2004-01-31 2009-10-21 Actimis Pharmaceuticals, Inc., Derivados del acido imidazo(1,2-c)pirimidinilacetico.
AU2005229522A1 (en) 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd. Indol-1-yl-acetic acid derivatives
DK1725553T3 (da) 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
CA2581335A1 (en) 2004-09-21 2006-03-30 Athersys, Inc. Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof
AU2005286718A1 (en) 2004-09-21 2006-03-30 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
CN101084190B (zh) 2004-12-27 2011-01-26 埃科特莱茵药品有限公司 作为crth2受体拮抗剂的2,3,4,9-四氢-1h-咔唑衍生物
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422830A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422829A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
AU2006216170B2 (en) 2005-02-25 2012-02-09 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
UA90145C2 (ru) 2005-05-24 2010-04-12 Лаборатуар Сероно С.А. Трициклические спиро-производные как модуляторы crth2
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
EP1916245B1 (en) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Indole derivative having pgd2 receptor antagonist activity
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
CA2618550C (en) 2005-08-12 2013-12-17 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
EP1931632A4 (en) 2005-08-18 2011-05-11 Microbia Inc USEFUL INDOOR CONNECTIONS
JP5147401B2 (ja) 2005-09-06 2013-02-20 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0525141D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
EP2125722A2 (en) 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
US7999119B2 (en) 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2066628B1 (en) 2006-07-25 2010-10-20 Sanofi-Aventis 2-phenyl-indoles as prostaglandin d2 receptor antagonists
CN101500996B (zh) 2006-08-07 2012-07-04 埃科特莱茵药品有限公司 (3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物
US20100010034A1 (en) 2006-12-21 2010-01-14 George Hynd Crth2 antagonists
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
JP2010522149A (ja) 2007-03-21 2010-07-01 アージェンタ オーラル セラピューティクス リミテッド Ｃｒｔｈ２アンタゴニストとしてのインドリジン酢酸誘導体
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
GB0719485D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
BRPI0815948A2 (pt) 2007-10-10 2019-09-24 Chemietek Llc "compostos heterocíclicos como antagonistas de receptorncrth2"
WO2009061676A2 (en) 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
PL2229358T3 (pl) 2007-12-14 2011-09-30 Pulmagen Therapeutics Asthma Ltd Związki indolowe i ich zastosowanie terapeutyczne
NZ587251A (en) 2008-01-18 2011-12-22 Oxagen Ltd Indole derivatives having CRTH2 antagonist activity
US20110060026A1 (en) 2008-01-18 2011-03-10 George Hynd Indoles Active on CRTH2 Receptor
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093026A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011088826A (ja) 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
WO2010008864A2 (en) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
CN102099341B (zh) 2008-07-15 2013-07-10 霍夫曼-拉罗奇有限公司 氨基四氢吲唑基乙酸类
WO2010006939A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
WO2010031182A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
WO2010031184A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Azaindole derivatives as crth2 receptor antagonists
US8637671B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
WO2010039982A1 (en) 2008-10-01 2010-04-08 Ironwood Pharmaceuticals, Inc. Crth2 modulators
GB2465062B (en) * 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010085820A2 (en) 2009-01-26 2010-07-29 Amira Pharmaceuticals, Inc. Tricyclic compounds as antagonists of prostaglandin d2 receptors
UA105039C2 (uk) 2009-02-24 2014-04-10 Мерк Шарп Енд Доме Корп. Похідні індолу як антагоністи рецептора crth2
WO2010142934A1 (en) 2009-06-12 2010-12-16 Pulmagen Therapeutics (Asthma) Limited Indole derivatives as ligands of crth2 receptors
EP2454264A1 (en) 2009-07-15 2012-05-23 Merck Serono S.A. Tricyclic indole-derived spiro derivatives as crth2 modulators
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
PL2558447T3 (pl) * 2010-03-22 2015-03-31 Idorsia Pharmaceuticals Ltd Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2
US20110311483A1 (en) 2010-03-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN103459389B (zh) 2011-04-14 2016-03-30 埃科特莱茵药品有限公司 7-(杂芳基-氨基)-6,7,8,9-四氢吡啶并[1,2-a]吲哚乙酸衍生物和其作为前列腺素D2受体调节剂的用途
CN103450218B (zh) 2012-05-29 2015-12-23 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类三并环衍生物
UA117780C2 (uk) * 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
KR20160133536A (ko) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도

Also Published As

Publication number Publication date
KR20180053345A (ko) 2018-05-21
EA201890726A1 (ru) 2018-10-31
PH12018500505A1 (en) 2018-09-24
ES2867757T3 (es) 2021-10-20
JP2018527411A (ja) 2018-09-20
HK1255148A1 (zh) 2019-08-09
US20190047996A1 (en) 2019-02-14
EP3350179B1 (en) 2021-01-13
WO2017046125A1 (en) 2017-03-23
TW201718578A (zh) 2017-06-01
JP6833852B2 (ja) 2021-02-24
CN108026093A (zh) 2018-05-11
CA2993893A1 (en) 2017-03-23
CN108026093B (zh) 2021-11-16
EA035752B1 (ru) 2020-08-05
UA123156C2 (uk) 2021-02-24
AU2016323262A1 (en) 2018-05-10
EP3350179A1 (en) 2018-07-25
TWI711616B (zh) 2020-12-01
US10351560B2 (en) 2019-07-16
AU2016323262B2 (en) 2020-11-19
MX379014B (es) 2025-03-10
PL3350179T3 (pl) 2021-08-02
CL2018000665A1 (es) 2018-07-13
IL258039A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
ECSP21072161A (es) Composiciones de liberación retardada de linaclotida
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2018005610A (es) Derivados de oxopiridina sustituidos
MX2019004685A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CL2016001895A1 (es) Compuestos
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112017001678A2 (pt) Método para a preparação de (4s)-4-(4-ciano-2- metoxi-fenil)-5-etoxi-2,8-dimetil-1,4-di-hidro-1-6- naftiridina-3-carboxiamida e purificação do mesmo para uso como um ingrediente ativo farmaceutico
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
DOP2014000081A (es) Compuestos y procedimientos para mejorar las respuestas inmunitarias innatas
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
ECSP16074478A (es) Compuestos novedosos
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
SV2018005657A (es) &#34;nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen&#34;
MX381590B (es) Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.
MX2018003202A (es) Formas cristalinas.